| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 32 | 33 | 36 | 39 | 43 | 87 | 94 | 119 | 155 | 174 | 153 | 150 |
| Expenses | 25 | 27 | 30 | 33 | 34 | 53 | 50 | 57 | 75 | 91 | 81 | 84 |
| EBITDA | 6 | 6 | 6 | 6 | 10 | 34 | 44 | 62 | 80 | 83 | 71 | 66 |
| Operating Profit % | 20 % | 19 % | 17 % | 16 % | 18 % | 37 % | 45 % | 51 % | 50 % | 46 % | 46 % | 43 % |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 5 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 5 | 5 | 5 | 5 | 8 | 31 | 41 | 59 | 78 | 79 | 66 | 60 |
| Tax | 0 | 0 | 1 | 1 | 2 | 8 | 11 | 15 | 20 | 20 | 17 | 14 |
| Net Profit | 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 59 | 49 | 45 |
| EPS in ₹ | 3.16 | 3.19 | 3.01 | 2.66 | 4.41 | 16.30 | 20.77 | 30.03 | 39.90 | 40.72 | 4.48 | 4.10 |
Gujarat Themis Biosyn
Gujarat Themis Biosyn
399.85
-11.90
(-2.89%)
Market Cap
4,357.00 Cr
EPS
4.48
PE Ratio
97.44
Dividend Yield
0.17 %
Industry
Healthcare52 Week High
424.90
52 Week Low
208.00
PB Ratio
17.48
Debt to Equity
0.07
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Gujarat Themis Biosyn Shareholders Approve All 10 Resolutions at 44th Annual General MeetingSep 12, 2025
Gujarat Themis Biosyn Limited held its 44th Annual General Meeting on September 12, 2025, where shareholders approved all 10 proposed resolutions with requisite majority. The resolutions included adoption of audited financial statements for the year ended March 31, 2025, declaration of dividend on equity shares, re-appointment of Dr. Dinesh S. Patel as director, appointment and re-designation of Dr. Sachin D. Patel as Managing Director, ratification of cost auditor remuneration for 2025-26, appointment of secretarial auditor, commission payments to directors, and appointment of Mr. Nihar Ajay Parikh as Independent Director. The meeting had 28,930 shareholders on record date with 61 shareholders present either in person or through proxy. Voting was conducted through remote e-voting and physical poll, with scrutinizer Mr. Ketan Shirwadkar overseeing the process.
Gujarat Themis Biosyn Reports 17.6% Drop in Net Profit, Announces 44th AGM for September 12Aug 19, 2025
Gujarat Themis Biosyn Limited reported a net profit of Rs 487.7 crores for FY2025, down 17.6% from Rs 591.6 crores in the previous year. Revenue declined 11.2% to Rs 1,532.3 crores from Rs 1,741.9 crores. The pharmaceutical intermediates and APIs manufacturer has scheduled its 44th Annual General Meeting for September 12, 2025. The Board recommended a dividend of Rs 0.67 per equity share. During the year, the company completed a bonus share issue in 1:2 ratio and commissioned a new API manufacturing facility. The Board initially approved a merger with Themis Medicare Limited but later decided not to proceed with the proposal.
Gujarat Themis Biosyn Reports Strong Q1 Results, Announces Board Changes and Dividend Record Date
Aug 01, 2025
Aug 01, 2025Gujarat Themis Biosyn Limited approved its unaudited standalone financial results for the quarter ended June 30, 2025. The company reported total income of ₹3,614.72 lakhs compared to ₹3,935.17 lakhs in the same quarter last year, with net profit after tax of ₹926.16 lakhs versus ₹1,323.62 lakhs in the previous year quarter. The board set September 5, 2025 as the record date for dividend distribution for the financial year ended March 31, 2025. In board composition changes, Nihar Parikh has been appointed as Additional Non-Executive Independent Director effective August 15, 2025, while Siddharth Kusumgar will cease to be Independent Director on September 20, 2025 upon completion of his second consecutive term. Parikh will replace Kusumgar on all board committees including Audit, Nomination & Remuneration, Corporate Social Responsibility, Stakeholders Relationship and Risk Management Committees. The company commenced commercial production at its new API plant in Vapi, Gujarat on May 1, 2025, designed for manufacturing Active Pharmaceutical Ingredients and intermediates for pharmaceutical industry use.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Forecast
Actual
Growth Rate
Revenue Growth
-12.46 %
Net Income Growth
-17.57 %
Cash Flow Change
41.77 %
ROE
-33.15 %
ROCE
-39.54 %
EBITDA Margin (Avg.)
-2.01 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 15 | 15 | 21 | 21 | 33 | 64 | 88 | 123 | 166 | 221 | 301 |
| Fixed Assets | 10 | 9 | 11 | 11 | 15 | 17 | 19 | 19 | 33 | 38 | 41 |
| Current Assets | 4 | 3 | 8 | 8 | 8 | 29 | 63 | 78 | 62 | 48 | 52 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 13 | 21 | 91 | 184 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 5 | 5 | 11 | 10 | 17 | 47 | 67 | 90 | 113 | 92 | 76 |
| Total Liabilities | 15 | 15 | 21 | 21 | 33 | 64 | 88 | 123 | 166 | 221 | 301 |
| Current Liabilities | 10 | 9 | 12 | 8 | 13 | 17 | 16 | 17 | 15 | 16 | 21 |
| Non Current Liabilities | 6 | 2 | 1 | 1 | 1 | 5 | 3 | 2 | 2 | 4 | 32 |
| Total Equity | -1 | 4 | 8 | 12 | 19 | 42 | 70 | 103 | 149 | 201 | 248 |
| Reserve & Surplus | -8 | -3 | 1 | 5 | 11 | 35 | 63 | 96 | 142 | 194 | 238 |
| Share Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 11 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | 0 | 0 | 1 | 0 | -0 | 3 | -4 | 6 | 0 | 5 |
| Investing Activities | -0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | -55 | -112 |
| Operating Activities | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 40 | 64 | 91 |
| Financing Activities | -3 | -3 | -0 | -4 | 5 | 2 | -5 | -14 | -13 | -9 | 26 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Feb 2025 | Mar 2025 | Jun 2025 |
| Promoter | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 70.86 % | 70.86 % | 70.86 % | 70.86 % | 70.86 % | 70.86 % | 70.86 % | 70.86 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 1.05 % | 1.44 % | 1.49 % | 1.42 % | 0.00 % | 1.91 % | 2.51 % |
| DIIs | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.02 % | 0.03 % | 0.03 % | 0.02 % | 0.82 % | 1.18 % | 1.17 % | 1.17 % | 1.16 % | 1.17 % | 1.17 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 22.07 % | 21.61 % | 21.89 % | 21.64 % | 21.30 % | 21.41 % | 21.60 % | 21.85 % | 22.09 % | 22.13 % | 21.85 % | 23.40 % | 22.26 % | 21.17 % | 20.44 % | 20.12 % | 19.75 % | 19.66 % | 19.31 % |
| Others | 2.90 % | 3.36 % | 3.08 % | 3.34 % | 3.67 % | 3.56 % | 3.38 % | 3.12 % | 2.90 % | 2.84 % | 3.11 % | 5.71 % | 5.00 % | 5.35 % | 6.03 % | 6.42 % | 8.22 % | 6.39 % | 6.14 % |
| No of Share Holders | 10,175 | 10,158 | 12,930 | 13,059 | 13,917 | 13,830 | 14,904 | 16,550 | 16,804 | 17,373 | 19,846 | 28,655 | 29,576 | 30,280 | 31,271 | 30,934 | 30,695 | 30,673 | 28,945 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1 | 0.67 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.17 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Nov 2021 |  Dividend | ₹ 5.00 /share | 24 Nov 2021 | 72.72 | 70.70 |
| 25 Nov 2021 | Dividend | ₹ 2.00 /share | 24 Nov 2021 | 76.39 | 70.70 |
| 31 Aug 2022 | Dividend | ₹ 4.00 /share | 29 Aug 2022 | 57.91 | 69.11 |
| 02 Dec 2022 | Dividend | ₹ 4.40 /share | 01 Dec 2022 | 118.27 | 107.17 |
| 02 Sept 2023 | Dividend | ₹ 1.00 /share | 01 Sept 2023 | 105.71 | 107.10 |
| 13 May 2023 |  Split | 1:5 | 10 Oct 2023 | 105.71 | 105.71 |
| 22 Feb 2024 | Dividend | ₹ 0.75 /share | 22 Feb 2024 | 232.97 | 227.63 |
| 16 Jul 2024 | Dividend | ₹ 0.25 /share | 15 Jul 2024 | 268.20 | 323.30 |
| 23 Jul 2024 |  Annual General Meeting | NA | 23 Jul 2024 | 268.20 | 311.07 |
| 09 Aug 2024 |  Bonus | 1:2 | 09 Aug 2024 | 327.30 | 337.70 |
| 25 Oct 2024 |  Quarterly Result Announcement | NA | 25 Oct 2024 | 324.65 | 298.95 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 299.15 | 260.50 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 314.45 | 334.05 |
| 01 Aug 2025 | Quarterly Result Announcement | NA | 01 Aug 2025 | 363.35 | 390.95 |
| 05 Sept 2025 | Dividend | ₹ 0.67 /share | 04 Sept 2025 | 334.05 | 381.30 |
| 12 Sept 2025 | Annual General Meeting | NA | 12 Sept 2025 | 362.30 | 381.05 |
Announcements
Closure of Trading Window2 days ago
2 days agoAnnouncement Under Regulation 30- Clarification4 days ago
4 days agoClarification sought from Gujarat Themis Biosyn Ltd4 days ago
4 days agoAnnouncement Under Regulation 30 (Updates)Sep 12, 2025
Sep 12, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 12, 2025
Sep 12, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 10, 2025
Sep 10, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Reg. 34 (1) Annual Report.Aug 19, 2025
Aug 19, 2025Annual General Meeting To Be Held On Friday 12Th September 2025Aug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 01, 2025
Aug 01, 2025Corporate Action- Fixes Record Date For Declaration Dividend For Financial Year 2024-25Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 01, 2025
Aug 01, 2025Un-Audited Financial Results For The Quarter Ended 30Th June 2025.Aug 01, 2025
Aug 01, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 1St August 2025Aug 01, 2025
Aug 01, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended 30Th June 2025Jul 26, 2025
Jul 26, 2025Compliances-Reg. 50 (1) - Prior intimation about Board meeting under Regulation 50(1)Jul 25, 2025
Jul 25, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 13, 2025
Jun 13, 2025Announcement Under Regulation 30 Of SEBI (LODR)- Withdrawal Of Scheme Of Amalgamation.Jun 13, 2025
Jun 13, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 13Th June 2025Jun 13, 2025
Jun 13, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Corporate Action-Board approves DividendMay 20, 2025
May 20, 2025Audited Financial Results For The Quarter And Year Ended 31St March 2025May 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)May 20, 2025
May 20, 2025Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31St March 2025May 15, 2025
May 15, 2025Announcement Under Regulation 30 (LODR) - UpdatesMay 06, 2025
May 06, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Intimation Of Listing Of Equity Shares Of The Company On National Stock Exchange Of India Limited (NSE).Feb 21, 2025
Feb 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Feb 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 14, 2025
Feb 14, 2025Integrated Filing (Financial)Feb 14, 2025
Feb 14, 2025Results - Financial Results For The Quarter And Nine Months Ended 31.12.2024Feb 14, 2025
Feb 14, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 14.02.2025Feb 14, 2025
Feb 14, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results And Limited Review Report For The Quarter And Nine Months Ended 31St December 2024.Feb 07, 2025
Feb 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Jan 10, 2025Announcement Under Regulation 30 (LODR) - Updates: Change In Name Of Registrar And Share Transfer Agent (RTA) Of The CompanyJan 02, 2025
Jan 02, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 05, 2024
Dec 05, 2024Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Nov 18, 2024
Nov 18, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 18, 2024
Nov 18, 2024Board Meeting Outcome for Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, ('Listing Regulations') - Outcome Of Board MeetingNov 18, 2024
Nov 18, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 09, 2024
Nov 09, 2024Technical Indicators
RSI(14)
Neutral 67.70
ATR(14)
Volatile 15.46
STOCH(9,6)
Neutral 71.22
STOCH RSI(14)
Overbought 96.50
MACD(12,26)
Bullish 2.75
ADX(14)
Weak Trend 24.46
UO(9)
Bearish 57.07
ROC(12)
Uptrend And Accelerating 8.09
WillR(14)
Neutral -25.34
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.09% | -2 | 0.00% | 0.01% | |
 Quant Manufacturing Fund Direct - Growth | 4.91% | 0 | 0.16% | 0.92% | |
| Quant Value Fund Direct - Growth | 0.58% | 0 | 0.01% | 0.09% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
